Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RECURSION PHARMACEUTICALS, INC.

(RXRX)
  Report
Real-time Estimate Cboe BZX  -  09:53 2022-09-26 am EDT
10.98 USD   +1.76%
09/23BEYOND THE DEAL : Recursion's Transformational Partnership with Roche and Genentech
PU
09/19RECURSION PHARMACEUTICALS, INC.(NASDAQGS : RXRX) added to S&P Biotechnology Select Industry Index
CI
09/16KeyBanc Starts Recursion Pharmaceuticals at Overweight With $20 Price Target
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2021 2022 2023 2024
Capitalization1 2 8951 867--
Enterprise Value (EV)1 2 3791 6151 7151 794
P/E ratio -11,5x-7,26x-6,88x-5,80x
Yield ----
Capitalization / Revenue 284x41,0x32,0x27,3x
EV / Revenue 234x35,5x29,4x26,3x
EV / EBITDA -13,6x-6,98x-6,41x-4,55x
Price to Book 5,37x5,36x5,01x6,06x
Nbr of stocks (in thousands) 168 993173 077--
Reference price (USD) 17,110,810,810,8
Announcement Date 03/23/2022---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2020 2021 2022 2023 2024
Net sales1 3,9610,245,558,468,3
EBITDA1 --174-231-268-394
Operating profit (EBIT)1 --183-231-273-366
Operating Margin --1 796%-506%-467%-536%
Pre-Tax Profit (EBT)1 --186-223-243-286
Net income1 -87,0-186-221-243-286
Net margin -2 196%-1 832%-485%-416%-419%
EPS2 -5,99-1,49-1,49-1,57-1,86
Dividend per Share2 -----
Announcement Date 03/03/202103/23/2022---
1 USD in Million
2 USD
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales1 2,535,337,676,9833,97,65
EBITDA1 ----58,4--
Operating profit (EBIT)1 -65,0-56,0-66,2-66,9-50,3-76,4
Operating Margin -2 565%-1 050%-863%-959%-149%-999%
Pre-Tax Profit (EBT)1 -64,9--65,6-61,0-18,0-
Net income1 -64,9-56,0-65,6-63,1-32,7-
Net margin -2 563%-1 050%-854%-905%-96,6%-
EPS2 -0,38-0,33-0,38-0,36-0,19-0,44
Dividend per Share ------
Announcement Date 03/23/202205/10/202208/09/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2020 2021 2022 2023 2024
Net Debt1 -----
Net Cash position1 -51625215273,8
Leverage (Debt / EBITDA) -2,96x1,09x0,57x0,19x
Free Cash Flow1 --198-139-267-305
ROE (Net Profit / Equities) --111%-42,7%-60,1%-76,7%
Shareholders' equity1 -168517405373
ROA (Net Profit / Asset) --41,0%-34,0%-38,4%-53,2%
Assets1 -454650633538
Book Value Per Share2 -3,192,012,151,78
Cash Flow per Share2 --1,27-0,21-1,37-
Capex1 -39,825,027,530,0
Capex / Sales -391%54,9%47,1%43,9%
Announcement Date 03/03/202103/23/2022---
1 USD in Million
2 USD
Estimates
Key data
Capitalization (USD) 1 867 497 495
Net sales (USD) 10 178 000
Number of employees 400
Sales / Employee (USD) 25 445
Free-Float 84,1%
Free-Float capitalization (USD) 1 570 903 781
Avg. Exchange 20 sessions (USD) 17 172 533
Average Daily Capital Traded 0,92%
EPS & Dividend